Prognostic performance of proteomic testing in advanced non-small cell lung cancer: a systematic literature review and meta-analysis

Ticiana A. Leal*, Angela C. Argento, Krish Bhadra, D. Kyle Hogarth, Julia Grigorieva, Rachel M. Hartfield, Robert C. McDonald, Philip D. Bonomi

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

4 Scopus citations


Objective: Timely assessment of patient-specific prognosis is critical to oncology care involving a shared decision-making approach, but clinical prognostic factors traditionally used in NSCLC have limitations. We examine a proteomic test to address these limitations. Methods: This study examines the prognostic performance of the VeriStrat blood-based proteomic test that measures the inflammatory disease state of patients with advanced NSCLC. A systematic literature review (SLR) was performed, yielding cohorts in which the hazard ratio (HR) was reported for overall survival (OS) of patients with VeriStrat Poor (VSPoor) test results versus VeriStrat Good (VSGood). A study-level meta-analysis of OS HRs was performed in subgroups defined by lines of therapy and treatment regimens. Results: Twenty-four cohorts met SLR criteria. Meta-analyses in five subgroups (first-line platinum-based chemotherapy, second-line single-agent chemotherapy, first-line EGFR-tyrosine kinase inhibitor (TKI) therapy, and second- and higher-line TKI therapy, and best supportive care) resulted in statistically significant (p ≤.001) summary effect sizes for OS HRs of 0.42, 0.54, 0.41, 0.52, and 0.50, respectively, indicating increased OS by about two-fold for patients who test VSGood. No significant heterogeneity was seen in any subgroup (p >.05). Conclusions: Advanced NSCLC patients classified VSGood have significantly longer OS than those classified VSPoor. The summary effect size for OS HRs around 0.4–0.5 indicates that the expected median survival of those with a VSGood classification is approximately 2–2.5 times as long as those with VSPoor. The robust prognostic performance of the VeriStrat test across various lines of therapy and treatment regimens has clinical implications for treatment shared decision-making and potential for novel treatment strategies.

Original languageEnglish (US)
Pages (from-to)1497-1505
Number of pages9
JournalCurrent Medical Research and Opinion
StatePublished - 2020


  • Meta-analysis
  • VeriStrat
  • prognosis
  • proteomic test

ASJC Scopus subject areas

  • Medicine(all)


Dive into the research topics of 'Prognostic performance of proteomic testing in advanced non-small cell lung cancer: a systematic literature review and meta-analysis'. Together they form a unique fingerprint.

Cite this